A new study published in Forensic Science International reveals that while alcohol and benzodiazepines have a clear and significant impact on driver impairment as their blood concentrations rise, the effects of THC are much less consistent and harder to predict, calling into question per se THC driving limits.

The research, which examined over 15,000 cases of impaired driving, highlights the complexity of assessing impairment from different substances, with alcohol and benzodiazepines showing a strong correlation between concentration and impairment, unlike THC and amphetamines.

The study aimed to determine how blood concentrations of ethanol, benzodiazepines, amphetamines, and tetrahydrocannabinol (THC) correlate with the severity of driver impairment, as measured by a Clinical Test of Impairment (CTI). Researchers utilized data from a national database, analyzing 15,514 individual mono-drug cases collected over nine years. The study population was predominantly male, with a median age of 34 years. In addition to these cases, 3,684 drug-free drivers with similar age and gender distribution were included as a reference group.
Continue reading

A new study published in the journal Frontiers in Immunology explores the potential role of cannabinoids in treating triple-negative breast cancer, a particularly aggressive form of breast cancer that accounts for 10-20% of all cases.

Conducted by researchers from the University of Ljubljana and the Institute of Oncology Ljubljana in Slovenia, the study examines how cannabinoids could influence standard therapies for triple-negative breast cancer (TNBC), which has historically been treated primarily with chemotherapy.

TNBC is known for its poor prognosis and limited treatment options. Recently, immune checkpoint inhibitors have emerged as a promising systemic treatment, yet there remains a need for tumor-specific biomarkers to enhance patient outcomes. The researchers highlight that cannabinoids, which have “demonstrated antitumor activity in preclinical TNBC models”, may not only complement chemotherapy but could also serve as potential biomarkers for immune checkpoint inhibitor therapy.
Continue reading

According to researchers at the University of Bonn and the Hebrew University of Jerusalem, the long-term, low-dose administration of tetrahydrocannabinol (THC) can reverse aging processes in the brain and may have broader anti-aging effects.

The study, recently published in the journal ACS Pharmacology & Translational Science, sheds light on the complex role of the protein switch mTOR (Mechanistic Target of Rapamycin) in aging and cognitive decline.

The research team, led by Prof. Dr. Andreas Zimmer, Director of the Institute of Molecular Psychiatry at the University Hospital Bonn, discovered that the mTOR protein is crucial in regulating metabolism and cognitive performance across the body. As a central hub for cell growth and metabolism, mTOR’s activity is highly responsive to intracellular energy levels. In higher organisms, mTOR activity significantly influences aging by regulating cellular metabolism.
Continue reading

Researchers at the University of Colorado Boulder have uncovered a potential breakthrough in autism prevention.

A new study, published in the journal Brain, Behavior, & Immunity – Health and also published online by the National Institute of Health, found that administering broad-spectrum cannabidiol (CBD) oil during pregnancy may prevent the development of autism-like behaviors in male offspring exposed to maternal stress.